Presented and published the positive results from both the Launch-HTN and Advance-HTN pivotal trials at scientific meetings and in JAMA and NEJM Pre-NDA meeting scheduled to take place in 4Q 2025 Explore-CKD Phase 2 trial successfully achieved statistical significance in reduction of systolic BP and UACR, and demonstrated a favorable safety profile Explore-OSA Phase 2 trial in OSA participants with hypertension is ongoing;... Read More

RADNOR, Pa., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc . (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as hypertensive nephropathy, obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the second quarter ended June 30,... Read More

The Launch-HTN trial is the largest trial of an aldosterone synthase inhibitor completed in participants with uncontrolled or treatment resistant hypertension Lorundrostat 50 mg once daily demonstrated clinically meaningful reductions in systolic blood pressure, with a 16.9 mmHg reduction at Week 6 and a 19.0 mmHg reduction at Week 12 Lorundrostat was generally well-tolerated; and treatment-emergent adverse events were... Read More

Explore-CKD met its primary endpoint; lorundrostat 25 mg once daily achieved a 9.3 mmHg reduction in systolic blood pressure, and a 7.5 mmHg placebo-adjusted reduction (p=0.0024) at four weeks Lorundrostat showed a clinically meaningful reduction in the pre-defined endpoint spot urine albumin-to-creatinine ratio of 31% (p<0.0001) Lorundrostat demonstrated a favorable safety and tolerability profile Conference call today at... Read More

Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated the efficacy of lorundrostat in over 1,000 participants with uncontrolled or resistant hypertension in a real-world setting Lorundrostat 50 mg dosed once daily demonstrated clinically meaningful and sustained reductions in systolic blood pressure, with a 16.9 mmHg reduction at Week 6 (-9.1 mmHg placebo adjusted) and a 19.0 mmHg reduction at... Read More

RADNOR, Pa., May 20, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced that data from the pivotal Phase 3 Launch-HTN trial evaluating the efficacy and safety of lorundrostat for... Read More

Pivotal Advance-HTN and Launch-HTN trials successfully achieved statistical significance in primary efficacy endpoints and demonstrated a favorable safety and tolerability profile Anticipate Explore-CKD Phase 2 trial to deliver topline data in Q2 2025 Initiated Explore-OSA Phase 2 Trial in Q1 2025 Conference call today at 4:30 p.m. ET RADNOR, Pa., May 12, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS),... Read More

RADNOR, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced that management will be participating in the Bank of America Securities 2025 Health Care Conference being... Read More

RADNOR, Pa., May 05, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the first quarter ended March 31, 2025, after the financial... Read More

Significant blood pressure reductions among patients with uncontrolled or resistant hypertension treated with lorundrostat reinforce key role of dysregulated aldosterone in disease onset and progression Detailed results from the second pivotal Phase 3 Launch-HTN trial to be presented at an upcoming medical conference and published in a peer-reviewed publication RADNOR, Pa., April 23, 2025 (GLOBE NEWSWIRE) -- Mineralys... Read More

Lorundrostat 50 mg dose achieved a 15.4 mmHg absolute reduction and 7.9 mmHg placebo-adjusted reduction (p=0.001), assessed by 24hr ABPM at week 12, with favorable safety and tolerability profile Lorundrostat is a highly selective aldosterone synthase inhibitor that disrupts aldosterone biosynthesis rather than blocking the mineralocorticoid receptor Data from Advance-HTN support the potential of lorundrostat as a... Read More

RADNOR, Pa., March 25, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced it will host a conference call and webinar featuring Dr. Luke Laffin of the Cleveland Clinic, who will... Read More

RADNOR, Pa., March 18, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today the closing of the sale of an additional 1,944,444 shares of its common stock at a public offering price... Read More

RADNOR, Pa., March 17, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea and other diseases driven by dysregulated aldosterone, today announced that data from the Phase 2 Advance-HTN trial evaluating the efficacy and safety of lorundrostat for the... Read More

RADNOR, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today the pricing of an underwritten public offering of 12,962,962 shares of its common stock at a public... Read More

RADNOR, Pa., March 10, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today that it has commenced an underwritten public offering of $250.0 million of shares of its common stock. In... Read More

Launch-HTN met its primary endpoint with lorundrostat 50 mg dose achieving a 16.9 mmHg reduction in systolic blood pressure, and a 9.1 mmHg placebo-adjusted reduction (p-value < 0.0001) assessed by automated office blood pressure at week 6 Launch-HTN met a predefined endpoint with lorundrostat 50 mg dose achieving a 19.0 mmHg reduction in systolic blood pressure, and an 11.7 mmHg placebo-adjusted reduction (p-value < 0.0001)... Read More

RADNOR, Pa., March 07, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced it will host a conference call and webinar to announce topline results from its Launch-HTN and... Read More

Anticipate topline data from pivotal Advance-HTN trial in March 2025 and pivotal Phase 3 Launch-HTN trial in mid first half of 2025 Completed enrollment in Explore-CKD Phase 2 trial and anticipate delivering topline data in Q2 2025 Initiating Phase 2 trial to evaluate lorundrostat for the treatment of patients with moderate-to-severe obstructive sleep apnea (OSA) and hypertension Conference call today at 8:30 a.m. ET RADNOR,... Read More

RADNOR, Pa., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the fourth quarter and full year ended December 31, 2024, before... Read More

RADNOR, Pa., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced that it has completed enrollment in the Explore-CKD Phase 2 trial evaluating the efficacy and safety of... Read More

Estimated 54 million people suffer from obstructive sleep apnea in the U.S. including 30-50% of adults with hypertension, both conditions associated with excess morbidity and mortality Obstructive sleep apnea represents Mineralys’ third precision, targeted indication for lorundrostat, further expanding its market potential in aldosterone-driven diseases Initiation of the trial anticipated in the first quarter of 2025 RADNOR,... Read More

Completed enrollment in pivotal Advance-HTN trial and anticipate topline data in March 2025 Completed enrollment ahead of schedule in pivotal Phase 3 Launch-HTN trial and anticipate delivering topline data in mid first half of 2025 Ongoing enrollment in Explore-CKD Phase 2 trial and anticipate delivering topline data in Q2 2025 Conference call today at 4:30 p.m. ET RADNOR, Pa., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Mineralys... Read More

RADNOR, Pa., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced that management will be participating in fireside chats at three upcoming investor conferences. Guggenheim Healthcare Innovation... Read More

RADNOR, Pa., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the third quarter ended September 30, 2024, after the financial markets close on Monday,... Read More

Topline data now anticipated in mid first half of 2025 Management to host virtual KOL event today to discuss the unmet need in hypertension, as well as a review of the ongoing pivotal clinical program for lorundrostat in hypertension RADNOR, Pa., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension,... Read More

RADNOR, Pa., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other prevalent cardiovascular diseases driven by dysregulated aldosterone, today announced full details for its upcoming virtual KOL event being held on Wednesday, October 30, 2024, at 10:00 AM ET. To... Read More

On track to announce topline data in Q1 2025 Virtual KOL event scheduled on October 30 th to discuss the unmet need in hypertension, as well as a review of the ongoing pivotal clinical program for lorundrostat in hypertension RADNOR, Pa., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic... Read More

RADNOR, Pa., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced that management will be participating in a fireside chat at the Wells Fargo Healthcare Conference, being held in Boston, MA on September... Read More

Advance-HTN trial is approximately 90% enrolled; trial is anticipated to deliver topline data in Q1 2025 Enrollment ahead of schedule in Phase 3 pivotal Launch-HTN trial and on track to deliver topline data as anticipated in 2H 2025 Ongoing Explore-CKD Phase 2 trial is ramping up enrollment under the amended protocol and is anticipated to deliver topline data in 1H 2025 Conference call today at 4:30 p.m. ET RADNOR, Pa., Aug.... Read More

RADNOR, Pa., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the second quarter ended June 30, 2024, after the financial markets close on Tuesday, August... Read More

RADNOR, Pa., June 14, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced that Alexander M. Gold, M.D. has been appointed to the Company's Board of Directors (the Board), effective June 13, 2024. “We are... Read More

RADNOR, Pa., June 03, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced that management will be participating in a fireside chat at the Goldman Sachs 45 th Annual Global Healthcare Conference, being held in... Read More

Advance-HTN trial of lorundrostat for the treatment of uHTN or rHTN is anticipated to deliver topline data in Q4 2024 Ongoing Phase 3 pivotal Launch-HTN trial of lorundrostat for the treatment of uHTN or rHTN is anticipated to deliver topline data in 2H 2025 Ongoing Explore-CKD Phase 2 trial is anticipated to deliver topline data in Q4 2024 to Q1 2025 Conference call today at 8:30 a.m. ET RADNOR, Pa., May 09, 2024 (GLOBE... Read More

RADNOR, Pa., May 06, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced that management will be participating in a fireside chat at the Bank of America Securities Health Care Conference, being held in Las Vegas... Read More

RADNOR, Pa., May 02, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the first quarter ended March 31, 2024, before the financial markets open on Thursday, May 9,... Read More

Enrollment in the two pivotal trials of lorundrostat for the treatment of uHTN or rHTN is on track, with topline data expected for Advance-HTN trial in Q4 2024 and Launch-HTN trial in 2H 2025 Explore-CKD Phase 2 trial, a study for lorundrostat in hypertensive patients with stage 2-3b CKD on track for Q4 2024 to Q1 2025 topline data Conference call today at 8:30 a.m. ET RADNOR, Pa., March 21, 2024 (GLOBE NEWSWIRE) --... Read More

RADNOR, Pa., March 13, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced it will report its financial results from the fourth quarter and full year ended December 31, 2023, before the financial markets... Read More

RADNOR, Pa., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (“CKD”) and other diseases driven by abnormally elevated aldosterone, today announced that it has entered into a securities purchase agreement with institutional accredited investors to sell securities in a private... Read More

RADNOR, Pa., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced that Chief Executive Officer Jon Congleton will be participating in a fireside chat at the Guggenheim Securities 6 th Annual... Read More

RADNOR, Pa., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced the appointment of Minji Kim, Ph.D. as Chief Business Officer. Adam Levy will remain in his role as Chief Financial Officer. “With... Read More

Topline data from confirmatory Launch-HTN trial expected in 2H 2025 Topline data from ongoing Advance-HTN pivotal trial expected in 2H 2024 RADNOR, Pa., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today... Read More

New analysis on serum leptin levels among patients in the Target-HTN Phase 2 trial adds to emerging evidence of positive feedback loop linking obesity, leptin and aldosterone Excess aldosterone in patients with visceral obesity defines a unique hypertensive endotype with potential for an enhanced response to aldosterone-targeted therapy with lorundrostat Early identification and intervention with lorundrostat may result in... Read More

RADNOR, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced that members of the senior management will be participating in the Stifel Healthcare Conference being held in New York on November... Read More

On track to initiate planned Phase 3 pivotal Launch-HTN trial of lorundrostat to treat patients with uncontrolled or resistant hypertension in 2H 2023 Expect to initiate planned Phase 2 Explore-CKD trial of lorundrostat alone and in combination with SGLT2 inhibitor to treat hypertensive patients with chronic kidney disease (CKD) in 2H 2023 Conference call today at 4:30 p.m. ET RADNOR, Pa., Nov. 07, 2023 (GLOBE NEWSWIRE) --... Read More

Analysis further supports obesity-associated dysregulated aldosterone as an endotype predictive of enhanced response to lorundrostat treatment in patients with uncontrolled or treatment-resistant hypertension Endotype identification from Target-HTN may represent a shift towards targeted, precision-directed therapy for hypertension management in future treatment paradigm Ongoing Advance-HTN trial, first of two pivotal... Read More

RADNOR, Pa., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced it will report its financial results from the third quarter ended September 30, 2023, after the financial markets close on... Read More

Late-breaking poster presentation at ASN’s Kidney Week 2023 Poster presentation at AHA’s Scientific Sessions 2023 RADNOR, Pa., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced upcoming poster... Read More

LOS ANGELES, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Praxis Bioresearch (“Praxis”), a biopharmaceutical company focused on the discovery and development of therapeutics for chronic neuropsychiatric and neurodegenerative disorders with an initial focus on apathy in Alzheimer’s Disease, today announced the appointment of Adam Levy to its Board of Directors (the “Board”). Mr. Levy brings executive, financial and operational... Read More

RADNOR, Pa., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced the appointments of Daphne Karydas and Glenn Sblendorio to its Board of Directors (the Board). Ms. Karydas and Mr. Sblendorio... Read More

RADNOR, Pa., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease and other diseases driven by abnormally elevated aldosterone, today announced that its Chief Executive Officer Jon Congleton, and Chief Financial Officer and Chief Business Officer, Adam Levy, will participate in... Read More

Lorundrostat, a highly selective aldosterone synthase inhibitor, demonstrated robust, double-digit reduction in systolic blood pressure (BP), including an enhanced response in individuals with elevated body mass index (BMI) Results simultaneously published in the Journal of the American Medical Association (JAMA) Pivotal clinical program for lorundrostat as a treatment of patients with uncontrolled and resistant hypertension... Read More

Lorundrostat, a highly selective aldosterone synthase inhibitor, demonstrated robust, double-digit reduction in systolic blood pressure (BP) with a well-tolerated profile Enhanced reduction in systolic BP seen in individuals with elevated body mass index (BMI) Robust trial design and results led to lorundrostat being first of new class, aldosterone synthase inhibitors, to start pivotal clinical program in hypertension... Read More

RADNOR, Pa., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease and other diseases driven by abnormally elevated aldosterone, today announced it has been selected to present the full results from the Target-HTN Phase 2 trial of lorundrostat in individuals with uncontrolled... Read More

RADNOR, Pa., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone, today announced that its Chief Executive Officer Jon Congleton, and Chief Financial Officer and Chief Business Officer, Adam Levy, will participate in a fireside chat at the Wells Fargo Securities... Read More

Continue enrolling subjects in ongoing pivotal Advance-HTN trial of lorundrostat, for the treatment of patients with uncontrolled or resistant hypertension On track to initiate planned Phase 3 pivotal Launch-HTN trial of lorundrostat for the treatment of uncontrolled or resistant hypertension in 2H 2023 Announced expansion of planned Phase 2 trial of lorundrostat alone and in combination with SGLT2 inhibitor to treat... Read More

RADNOR, Pa., July 31, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone, today announced it will report its financial results from the second quarter ended June 30, 2023, after the financial markets close on Monday, August 7, 2023. Monday, August 7 th @ 4:30 p.m. ET... Read More

Plan to initiate a Phase 2 proof of concept trial of lorundrostat alone and in combination with an SGLT2 inhibitor for CKD in the second half of 2023 Profiling trial of safety in individuals with stage 3b and 4 CKD to support the hypertension indication will be run in parallel The program builds on the established role of aldosterone in the progression of CKD RADNOR, Pa., July 17, 2023 (GLOBE NEWSWIRE) -- Mineralys... Read More

RADNOR, Pa., May 31, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone, today announced that its Chief Executive Officer Jon Congleton, and Chief Financial Officer and Chief Business Officer, Adam Levy, will be giving a presentation at the Jefferies Healthcare Conference... Read More

Commenced patient dosing in lorundrostat pivotal clinical program, for the treatment of patients with uncontrolled or resistant hypertension in April 2023 Plan to initiate the second pivotal trial to evaluate the safety and efficacy of lorundrostat for the treatment of uncontrolled or resistant hypertension in the second half of 2023 Plan to initiate a Phase 2 trial to evaluate the safety and efficacy of lorundrostat for the... Read More

Topline data from the trial are expected in the first half of 2024 A second, pivotal trial of lorundrostat in uncontrolled and resistant hypertension expected to commence enrollment in the second half of 2023 RADNOR, Pa., May 02, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated... Read More

RADNOR, Pa., May 01, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone, today announced it will report its financial results from the first quarter ended March 31, 2023, after the financial markets close on Monday, May 15, 2023. The Company’s management team will host a... Read More

RADNOR, Pa., April 27, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone, today announced that its Chief Executive Officer Jon Congleton and Chief Financial Officer and Chief Business Officer Adam Levy will participate in a fireside chat at the Bank of America Securities... Read More

Lorundrostat pivotal clinical program, for the treatment of patients with uncontrolled hypertension, expected to begin in the first half of 2023 IPO and Nasdaq listing completed in February 2023 with total net proceeds of approximately $202.0 million, after deducting underwriting discounts, commissions and estimated offering costs Conference call today at 4:30 p.m. ET RADNOR, Pa., March 15, 2023 (GLOBE NEWSWIRE) -- Mineralys... Read More

Lorundrostat demonstrated clinically meaningful blood pressure reduction in individuals with uncontrolled hypertension Obesity was predictive of an enhanced response to lorundrostat with placebo-adjusted systolic BP reduction of 16.7 mmHg with 50mg once-daily dosing Additional clinical trial expected to begin in first half of 2023 RADNOR, Pa., March 04, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a... Read More